{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:17Z","timestamp":1790916977616,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The current American Joint Committee on Cancer (AJCC) staging system defines cN1 by node mobility rather than number, while pathologic staging stratifies by node count. Whether cN1 patients with four or more suspicious nodes on pretreatment imaging differ in pathologic stage and survival outcomes from those with fewer nodes is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Patients with biopsy-proven cN1 or cN2a breast cancer diagnosed in 2018\u20132023 who received neoadjuvant chemotherapy (NAC) at a single institution were identified. Pretreatment imaging was reviewed and cases categorized as cN1a (1\u20133 mobile nodes), cN1b (\u2265 4 mobile nodes), or cN2a (matted nodes). Clinicopathologic characteristics were compared using\n                      <jats:italic>\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      and Kruskal\u2013Wallis tests. DFS and OS were estimated with Kaplan\u2013Meier curves and multivariable Cox regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 618 cases, 390 (63.1%) were cN1a, 166 (26.9%) cN1b, and 62 (10.0%) cN2a. Pathologic complete response (pCR) rates did not differ across groups (29.5%, 28.9%, 35.5%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.598). Among patients with residual nodal disease, mean positive nodes were 2.8, 4.6, and 5.5 in cN1a, cN1b, and cN2a (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001), respectively. Pathologic nodal stage was ypN2 or higher in 12.8%, 24.1%, and 29.0% (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.001), and cN1b was independently associated with upstaging on multivariable analysis (OR 1.958, 95% CI 1.184\u20133.237,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009). At median follow-up of 41.4 months, 3-year DFS (88.0%, 89.0%, 80.6%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.949) and OS (91.6%, 92.3%, 91.6%;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.947) did not differ across groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In cN1 breast cancer, imaging-defined nodal burden \u2265 4 nodes independently predicts upstaging and greater residual nodal burden after NAC, aligning pathologically with cN2a disease. Imaging-based subcategorization of cN1 disease may have implications for staging, surgical planning, and trial eligibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20128-y","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:51:38Z","timestamp":1784209898000},"page":"9719-9727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is It Time to Redefine Clinical Nodal Staging for Breast Cancer?"],"prefix":"10.1245","volume":"33","author":[{"given":"Pooja M.","family":"Varman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Taft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Matar-Ujvary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Ilkanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Al-Hilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"5","key":"20128_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ijrobp.2012.11.005","volume":"85","author":"C Dai Kubicky","year":"2013","unstructured":"Dai Kubicky C, Mongoue-Tchokote S. Prognostic significance of the number of positive lymph nodes in women with T1\u20132N1 breast cancer treated with mastectomy: should patients with 1, 2, and 3 positive lymph nodes be grouped together? Int J Radiat Oncol Biol Phys. 2013;85(5):1200\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.11.005.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"8","key":"20128_CR2","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1200\/JCO.1999.17.8.2334","volume":"17","author":"I Jatoi","year":"1999","unstructured":"Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(8):2334\u201340. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2334.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"7","key":"20128_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/jclinpath-2012-200755","volume":"65","author":"EA Rakha","year":"2012","unstructured":"Rakha EA, Morgan D, Macmillan D. The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. J Clin Pathol. 2012;65(7):624\u201330. https:\/\/doi.org\/10.1136\/jclinpath-2012-200755.","journal-title":"J Clin Pathol."},{"issue":"6","key":"20128_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJM199208063270606","volume":"327","author":"JR Harris","year":"1992","unstructured":"Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer. N Engl J Med. 1992;327(6):390\u20138. https:\/\/doi.org\/10.1056\/NEJM199208063270606.","journal-title":"N Engl J Med."},{"issue":"1","key":"20128_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.04.073","volume":"77","author":"P Tai","year":"2010","unstructured":"Tai P, Yu E, Joseph K. Prognostic significance of number of positive nodes: a long-term study of one to two nodes versus three nodes in breast cancer patients. Int J Radiat Oncol Biol Phys. 2010;77(1):180\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.073.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"20128_CR6","doi-asserted-by":"publisher","unstructured":"Le-Petross HT, Slanetz PJ, Lewin AA, et al. ACR Appropriateness Criteria\u00ae imaging of the axilla. J Am Coll Radiol. 2022;19(5, Supplement):S87-S113. https:\/\/doi.org\/10.1016\/j.jacr.2022.02.010","DOI":"10.1016\/j.jacr.2022.02.010"},{"issue":"5","key":"20128_CR7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/jmri.28399","volume":"57","author":"Z Li","year":"2023","unstructured":"Li Z, Gao Y, Gong H, et al. Different imaging modalities for the diagnosis of axillary lymph node metastases in breast cancer: a systematic review and network meta-analysis of diagnostic test accuracy. J Magn Reson Imaging JMRI. 2023;57(5):1392\u2013403. https:\/\/doi.org\/10.1002\/jmri.28399.","journal-title":"J Magn Reson Imaging JMRI."},{"issue":"12","key":"20128_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2967\/jnumed.121.262009","volume":"62","author":"J Morawitz","year":"2021","unstructured":"Morawitz J, Bruckmann NM, Dietzel F, et al. Determining the axillary nodal status with four current imaging modalities including 18F-FDG PET\/MRI in newly diagnosed breast cancer: a comparative study using histopathology as reference standard. J Nucl Med Off Publ Soc Nucl Med. 2021;62(12):1677\u201383. https:\/\/doi.org\/10.2967\/jnumed.121.262009.","journal-title":"J Nucl Med Off Publ Soc Nucl Med."},{"issue":"2","key":"20128_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2214\/AJR.19.22022","volume":"214","author":"SX Sun","year":"2020","unstructured":"Sun SX, Moseley TW, Kuerer HM, Yang WT. Imaging-based approach to axillary lymph node staging and sentinel lymph node biopsy in patients with breast cancer. Am J Roentgenol. 2020;214(2):249\u201358. https:\/\/doi.org\/10.2214\/AJR.19.22022.","journal-title":"Am J Roentgenol."},{"issue":"3","key":"20128_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2214\/AJR.12.9036","volume":"200","author":"H Abe","year":"2013","unstructured":"Abe H, Schacht D, Sennett CA, Newstead GM, Schmidt RA. Utility of preoperative ultrasound for predicting pN2 or higher stage axillary lymph node involvement in patients with newly diagnosed breast cancer. Am J Roentgenol. 2013;200(3):696\u2013702. https:\/\/doi.org\/10.2214\/AJR.12.9036.","journal-title":"Am J Roentgenol."},{"issue":"7","key":"20128_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ejso.2018.04.003","volume":"44","author":"GH Lim","year":"2018","unstructured":"Lim GH, Upadhyaya VS, Acosta HA, Lim JMA, Allen JC, Leong LCH. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2018;44(7):945\u201350. https:\/\/doi.org\/10.1016\/j.ejso.2018.04.003.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."},{"key":"20128_CR12","doi-asserted-by":"publisher","unstructured":"Elsholtz FHJ, Asbach P, Haas M, et al. Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol. 2021;31(8):6116-6124. https:\/\/doi.org\/10.1007\/s00330-020-07572-4","DOI":"10.1007\/s00330-020-07572-4"},{"issue":"9938","key":"20128_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet."},{"key":"20128_CR14","unstructured":"Alliance for Clinical Trials in Oncology. A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. clinicaltrials.gov; 2025. Accessed March 27, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01901094"},{"issue":"9","key":"20128_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild SR, de Munck L, Simons JM, et al. De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010\u201303): 5-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2022;23(9):1201\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(22)00482-X.","journal-title":"Lancet Oncol."},{"issue":"21","key":"20128_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","volume":"392","author":"EP Mamounas","year":"2025","unstructured":"Mamounas EP, Bandos H, White JR, et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025;392(21):2113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2414859.","journal-title":"N Engl J Med."},{"issue":"5","key":"20128_CR17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1148\/rg.2021210053","volume":"41","author":"HL Chung","year":"2021","unstructured":"Chung HL, Le-Petross HT, Leung JWT. Imaging updates to breast cancer lymph node management. RadioGraphics. 2021;41(5):1283\u201399. https:\/\/doi.org\/10.1148\/rg.2021210053.","journal-title":"RadioGraphics."},{"issue":"3","key":"20128_CR18","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.243823","volume":"316","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Chae EY, Eom HJ, et al. Node Reporting and Data System evaluation of axillary nodes in invasive ductal and lobular carcinoma. Radiology. 2025;316(3):e243823. https:\/\/doi.org\/10.1148\/radiol.243823.","journal-title":"Radiology."},{"issue":"12","key":"20128_CR19","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1007\/s00330-024-10828-y","volume":"34","author":"F Pediconi","year":"2024","unstructured":"Pediconi F, Maroncelli R, Pasculli M, et al. Performance of MRI for standardized lymph nodes assessment in breast cancer: are we ready for Node-RADS? Eur Radiol. 2024;34(12):7734\u201345. https:\/\/doi.org\/10.1007\/s00330-024-10828-y.","journal-title":"Eur Radiol."},{"key":"20128_CR20","doi-asserted-by":"publisher","unstructured":"Parillo M, Quattrocchi CC. Node Reporting and Data System 1.0 (Node-RADS) for the assessment of oncological patients\u2019 lymph nodes in clinical imaging. J Clin Med. 2025;14(1):263. https:\/\/doi.org\/10.3390\/jcm14010263","DOI":"10.3390\/jcm14010263"},{"issue":"11","key":"20128_CR21","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1634\/theoncologist.2017-0116","volume":"22","author":"M Chavez-MacGregor","year":"2017","unstructured":"Chavez-MacGregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating tumor characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. The Oncologist. 2017;22(11):1292\u2013300. https:\/\/doi.org\/10.1634\/theoncologist.2017-0116.","journal-title":"The Oncologist."},{"issue":"6","key":"20128_CR22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","volume":"25","author":"KT Hwang","year":"2019","unstructured":"Hwang KT, Kim J, Jung J, et al. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER database. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(6):1970\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2782.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"8","key":"20128_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31078","volume":"6","author":"G Liu","year":"2023","unstructured":"Liu G, Kong X, Dai Q, et al. Clinical features and prognoses of patients with breast cancer who underwent surgery. JAMA Netw Open. 2023;6(8):e2331078. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31078.","journal-title":"JAMA Netw Open."},{"key":"20128_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41523-020-0152-4","volume":"6","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Song J, Raghavendra AS, et al. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer. 2020;6:11. https:\/\/doi.org\/10.1038\/s41523-020-0152-4.","journal-title":"NPJ Breast Cancer."},{"key":"20128_CR25","doi-asserted-by":"publisher","first-page":"1265304","DOI":"10.3389\/fonc.2023.1265304","volume":"13","author":"Y Xie","year":"2023","unstructured":"Xie Y, Deng Y, Wei S, et al. Age has a U-shaped relationship with breast cancer outcomes in women: a cohort study. Front Oncol. 2023;13:1265304. https:\/\/doi.org\/10.3389\/fonc.2023.1265304.","journal-title":"Front Oncol."},{"issue":"10075","key":"20128_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2.","journal-title":"Lancet."},{"issue":"1","key":"20128_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-022-06718-w","volume":"196","author":"CEP Smith","year":"2022","unstructured":"Smith CEP, Marcom PK, Mitri Z, Ko NY. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions. Breast Cancer Res Treat. 2022;196(1):215\u201320. https:\/\/doi.org\/10.1007\/s10549-022-06718-w.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"20128_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H","volume":"63","author":"CL Carter","year":"1989","unstructured":"Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181\u20137.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20128-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20128-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20128-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:50:48Z","timestamp":1790916648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20128-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20128"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20128-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zahraa AlHilli reports consulting fee from AbbVie not relevant to this work.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}